Financial Release TSPC YTD SEP-24.pdf

Under the abovementioned challenging circumstances, PT Tempo Scan Pacific,
Tbk. (Tempo Scan) YTD September 2024 net sales result was able to register a
commendable net sales increase of almost 4.0 Yo and amounted to Rp.10,150.4 billion,
such a result was mainly attributed by its Pharmaceutical division and Consumer
Products & Cosmetics (“CPC”) division net sales stellar performance which
respectively grew by 19.2”o and 10.5Yo. On the other hand, its Distribution
division which net sales comprises of Tempo Scan external principals' products had
decreased considerably by 13.3Y0.

Moreover, Tempo Scan's YTD September 2024 aforesaid consolidated net sales
performance major benefactors were as follows:

1) Tempo Scan's Pharmaceutical division was able to deliver its net sales
stellar growth which grew high double digits by 19.2”/0 and amounted
to Rp.3,543.4 billion, such a net sales growth was significantly higher when
compared to its growth in the same period last year which grew only by 12.1Y6.

This division net sales growth main benefactor remained to be its Consumer
Health products group which net sales had increased commensurately
by 19.6Yo and amounted to Rp.3,485.2 billion. This Consumer Health
group's commendable net sales increase was propelled by its Nutritional
products' net sales which has risen exponentially by 40.80 year on
year. The said Nutritional products rapid sales growth transpired on a nationwide
basis as consumers demand surged substantially across all sales channels and
geographical regions. While similar positive net sales performance was also
exhibited by the Consumer Health group's OTC and Vitamins products which net
sales increased by 3.6Y6, despite the overall OTC market challenging condition.

Moving ahead, Tempo Scan is continuously monitoring consumers slowing
demand which corresponding to their declining buying power, since such a
condition may potentially trigger precipitous price discounting and even
permanent price reductions in the overall pharmaceutical and nutritional products
Categories as competitive pressure is intensifying leading to year end.

On the other hand, Tempo Scan Pharmaceutical division Prescription Medicine
products" net sales decreased by 0.4Yo and amounted to Rp.58.2 billion.
Conseguenttly, for YTD September 2024 Tempo Scan's Consumer Health products
group and its Prescription Medicines group net sales contributions toward its
Pharmaceutical division's total net sales were 98.474 and 1.6Yo respectively.

In addition, the Pharmaceutical division's international business net sales had
increased by 7.4Yo and amounted to Rp.202.8 billion, such a net sales result was
lower compared to its net sales in the corresponding period last year which grew
by 9.2Yo. Correspondingly, the aforementioned international business net sales
contribution towards Tempo Scan's Pharmaceutical division total net sales was
5.7Yo or lower when compared to its net sales contribution of 6.499 in the same
period last year.

Page | 2 4

2) Tempo Scan's Consumer Products & Cosmetics (“CPC”) division has also

3)

been able to register a commendable net sales growth which increased
by 10.50 and amounted to Rp.3,336.0 billion. This division's net sales
primary benefactor continues to be its Consumer Products group which net sales
increased commendably by 11.696 and amounted to Rp.2,706.4 billion. While its
Cosmetics group's net sales performance delivered a lesser growth rate of 6.1Yo
and amounted to Rp.629.5 billion.

The Consumer Products group's core brand eguities have solid and well establish
market positions, henceforth these brands' products are well poised to face the
FMCG market conundrum related to the ongoing market weakness. There were
several major FMCG companies have become desperate and reluctantly engaged
in a discount war and forced to cut their products price in order to defend their
products dwindling market shares.

Moreover, the CPC division's Consumer Products group and Cosmetics group net
sales contributions toward this division total net sales were 81.1Yc and 18.9Yo
respectively for YTD September 2024, such a contribution was marginally changed
when compared to these net sales contributions in the same period last year which
were at 80.3Yo and 19.7Y4o respectively.

For YTD September 2024, the CPC division's International Business net sales was
able to maintained its robust growth and registered a net sales increase of 19.0Y9.
Sucha strong net sales performance was contributed by both of its
Consumer Products and Cosmetics which net sales have increased by
31.270 and 16.00 respectively. Conseguently, this CPC division's
International Business net sales contribution towards its total net sales had
increased to become 4.2Y6 versus its net sales contribution in YTD September
2023 which stood at 3.9Ys.

Tempo Scan's Distribution division net sales decreased by 13.3Y6 and amounted
to Rp.3,271.0 billion. Its main contributor of this division net sales growth was its
Non-Pharma Principals' products which net sales decreased by 15.2Y6 and
amounted to Rp.2,955.6 billion, while on the other hand this division Pharma
Principals' products registered an increase of 9.0Yo and amounted to Rp.315.4
billion. Correspondingly, the aforesaid Non-Pharma Principals' products and
Pharma Principals' products net sales contributions toward the Distribution division
total net sales stood at 90.4Y6 and 9.6Yo respectively for YTD September 2024,
such a contribution was marginally changed when compared to these net sales
contributions the same period last year which were at 92.3Y6 and 7.7Y0
respectively.

Page | 3 4

Furthermore, for YTD September 2024Tempo Scan's gross profit result
registered a significant increase of 13.90 and amounted to Rp.3,854.6
billion, such an increase was significantly higher compared to its net sales growth
rate, as a result its gross profit margin had also increased significantly to
become 38.070 versus its gross profit margin in the corresponding period
last year which was 34.6Yo.

Such a gross profit margin commendable performance was amongst other attributed
to its sales mix change, whereas for YTD September 2024 Tempo Scan Pharmaceutical
and CPC divisions net sales contribution have risen considerably to become almost
70Yo of Tempo Scan's consolidated net sales. These 2 divisions have generated
significantly higher gross profit margin vis-a-vis its Distribution division which net sales
contribution has also declined and generated much lower gross profit margin.

Moving on to Tempo Scan's total operating expenses for YTD September 2024, it has
decreased by 6.6Yo and amounted to Rp.2,401.1 billion, such a decrease was
attributed amongst others by its total selling expenses that had declined by 6.7Yo and
amounted to Rp.1,897.7 billion. Conseguently, this total selling expenses as a ratio to
Tempo Scan's consolidated net sales was 18.7Yo or lower compared to the same
period last year whereas such ratio was 20.8Y9.

On the other hand, its total general administrative expenses increased by 6.5Yo and
amounted to Rp.491.5 billion, hence the said total general administrative expenses
ratio towards Tempo Scan's consolidated net sales was 4.8Y9 or slightly higher
compared to the ratio in the same period last year which was 4.7Y6.

Moreover, Tempo Scan's net other operating expenses had considerably decreased by
84.1Yo and amounted to Rp.11.9 billion, such a decrease was predominantly caused
by its lower foreign exchange loss.

Notwithstanding the above, Tempo Scan's operating profit in YTD September
2024 managed to register meteoric rise of 78.6”o and amounted to
Rp.1,453.5 billion, hence its operating profit margin has also increased to
become 14.3Yo, higher compared to the same period last year whereas its
operating profit margin was only 8.3Yo.

Furthermore, for YTD September 2024 its net non-operating income had decreased
and amounted to Rp.94.9 billion or lower compared to corresponding period last year
which amount was Rp.476.2 billion. This decrease was mainly attributed to the one-
time gain registered previously in YTD September 2023. As the result, Tempo Scan's
YTD September 2024 net profit after tax has increased by 13.7Yo and
amounted to Rp.1,082.7 billion, commensurately its net profit after tax margin
stood at 10.7Y6 or higher versus its net profit after tax margin in the same period
previous year which was 9.7Y0.

Page | 4

As furtherance to the above, Tempo Scan's EBITDA has significantly risen by
61.590 and amounted to Rp.1,709.0 billion, hence its EBITDA margin for
YTD September 2024 stood at 16.8Yo or sharply higher compared to its
EBITDA margin in the corresponding period last year which was at 10.8Yo.

As pertained to Tempo Scan's balance sheet position as of 30 September 2024, it
remained solid whereas its cash and cash eguivalent position total amount stood at
Rp.3,928.6 billion or an increase of 8.4Yo compared to corresponding period last year.
In addition, its net operating cycle was at 77 days despite the challenging market
liguidity condition. Lasty Tempo's Scan total assets and shareholders' eguity
were amounted to Rp.12,167.7 billion and Rp.8,944.3 billion respectively.

Tempo Scan's Board of Directors would like to express our highest appreciation to all
Tempo Scan's Board Commissioners, its management team and all of its employees
for their continuous support, advise, dedication, commitment and hard works. As well
as to our valued shareholders, business partners, vendors, customers and professional
parties that has made Tempo Scan can achieved the abovementioned financial
results.

Jakarta, 30 October 2024
On behalf of PT. Tempo Scan Pacific, Tbk.

Liza Prasodjo
Chief Financial Officer

Copies:

- Mr. Handojo S. Muljadi, Tempo Scan's Executive Chairman
- Tempo Scan's Board of Directors

Page | 5